Empagliflozin (Jardiance) Market
Report ID: SQMIG35I3479
Report ID: SQMIG35I3479
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I3479 |
Region:
Global |
Published Date: August, 2026
Pages:
157
|Tables:
116
|Figures:
77
Global Empagliflozin (Jardiance) Market size was valued at USD 18.62 Billion in 2024 and is poised to grow from USD 20.74 Billion in 2025 to USD 49.2 Billion by 2033, growing at a CAGR of 11.4% during the forecast period (2026-2033).
Empagliflozin, marketed as Jardiance, anchors the SGLT2‑inhibitor segment, a market of diabetes therapeutics that expanded rapidly after its 2014 FDA approval. The primary driver of this growth is the drug’s proven ability to lower cardiovascular mortality in type‑2 diabetes, a benefit confirmed by the EMPA‑REG OUTCOME trial and reproduced in registries. By delivering glucose control and heart‑failure reduction, empagliflozin reshaped prescribing habits, prompting insurers to favor it over older agents and encouraging firms to develop molecules. Consequently, the market rose from niche sales in 2015 to a billion portfolio that now shapes treatment guidelines across North America, Europe and economies.
Building on this foundation, the key trend driving the global empagliflozin (jardiance) sector is its expanding indication set, especially in heart‑failure and chronic kidney disease, where trial evidence such as EMPEROR‑Reduced creates physician confidence and drives formulary inclusion and higher reimbursement, opening revenue streams beyond diabetes. Real‑world programs in the United States and Germany show multidisciplinary pathways that incorporate Jardiance, boosting adherence and cutting hospitalizations, which in turn attract payors seeking value‑based contracts. Consequently, manufacturers forecast sustained double‑digit growth through 2028 globally as expansion into Asia‑Pacific aligns with rising metabolic disease prevalence and supportive health‑policy reforms in key emerging markets.
How is AI-Driven Data Analytics Reshaping the Empagliflozin (Jardiance) Market?
AI‑driven data analytics is redefining the Empagliflozin market by turning vast patient data into actionable insights. Advanced algorithms sift through electronic health records, claims data and wearable metrics to pinpoint which diabetes patients respond best to Jardiance, to forecast adherence patterns and to highlight safety signals earlier than traditional methods. This real‑time intelligence enables clinicians to tailor therapy, reduces trial‑and‑error prescribing and supports payers in designing value‑based contracts. Manufacturers can now align launch strategies with regional utilization trends, while researchers use predictive modeling to explore new indications such as heart failure. The result is a more efficient ecosystem where evidence flows faster and decisions are increasingly data‑backed.
In April 2026, Boehringer Ingelheim announced a £150 million investment to establish an AI and machine learning accelerator in London, strengthening computational drug discovery and disease research capabilities. The initiative supports AI-driven identification of therapeutic targets and lifecycle innovation across its portfolio, including Jardiance (empagliflozin), to accelerate future cardio-renal-metabolic treatment development.
Market snapshot - (2026-2033)
Global Market Size
USD 18.62 Billion
Largest Segment
Type 2 Diabetes
Fastest Growth
Chronic Kidney Disease
Growth Rate
11.4% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global empagliflozin (jardiance) market is segmented by indication, dosage strength, distribution channel, end user and region. Based on indication, the market is segmented into type 2 diabetes, heart failure and chronic kidney disease. Based on dosage strength, the market is segmented into 10 mg and 25 mg. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on end user, the market is segmented into hospitals, clinics and home care. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Based on the global empagliflozin (jardiance) market growth, type 2 diabetes segment dominates because it represents the original therapeutic indication for empagliflozin, driving the bulk of prescribing volume. Clinicians prioritize this indication due to extensive clinical evidence, reimbursement pathways, and established treatment algorithms, which collectively create a stable demand base. The entrenched guidelines and patient familiarity reinforce its market leadership, ensuring continuous supply chain focus and promotional investment. Pharmacy networks also allocate preferred formulary status, further cementing its dominance.
However, heart failure segment is witnessing the strongest growth momentum as clinicians expand empagliflozin use beyond glucose control to cardiac outcome improvement. Emerging trial data and guideline endorsements stimulate prescribing confidence, while hospital formularies prioritize the therapy for high risk patients. This expanding therapeutic relevance fuels rapid market uptake and creates revenue streams.
Hospital pharmacies segment leads because they serve as primary access points for inpatient empagliflozin prescribing, especially for acute cardiometabolic conditions. Institutional formularies streamline approval processes, and integrated electronic medical records facilitate rapid order entry, reinforcing consistent utilization. The concentration of specialist physicians and multidisciplinary care teams within hospitals amplifies therapeutic adoption, while bulk purchasing agreements reduce cost barriers, consolidating the channel’s leadership role and ensure steady inventory turnover throughout the year.
Meanwhile, online pharmacies segment emerges as the key high growth area as patients increasingly prefer home delivery and telehealth integration for chronic disease management. Digital prescribing platforms simplify refill processes, while direct to consumer marketing expands awareness. This convenience driven adoption accelerates market penetration and opens avenues for innovative subscription models.
To get detailed segments analysis, Request a Free Sample Report
As perthe global empagliflozin (jardiance) market share, North America maintains dominance through a combination of mature healthcare systems, strong reimbursement frameworks, and high awareness among clinicians of the therapeutic benefits of empagliflozin. Payers in the region provide favorable coverage policies that encourage adoption, while leading academic and clinical networks disseminate practice guidelines that position the drug prominently in treatment algorithms. Pharmaceutical companies leverage extensive sales forces and robust patient‑support programs to deepen market penetration. Moreover, the presence of a large, insured patient population with a high prevalence of type two diabetes creates a steady demand stream, reinforcing the region’s leadership. Continuous investment in real‑world evidence generation further consolidates confidence among prescribers, ensuring that empagliflozin remains a cornerstone therapy across diverse care settings.
Empagliflozin (jardiance) market in United States is supported by an extensive network of specialty pharmacies and integrated care pathways that streamline prescription and monitoring processes. Aggressive education initiatives targeting endocrinologists and primary care physicians foster early adoption, while patient assistance programs mitigate out‑of‑pocket costs. The collaborative environment between insurers, providers, and manufacturers sustains a high level of formulary placement, encouraging consistent use across the diabetic population.
Empagliflozin (jardiance) market in Canada benefits from a publicly funded health system that emphasizes evidence‑based therapeutics and cost‑effectiveness assessments. Provincial drug formularies often include the medication as a preferred option, facilitating broad accessibility. Clinical consensus groups regularly update treatment pathways to highlight the drug’s cardiovascular and renal benefits, reinforcing its role in standard care. Patient support initiatives and educational outreach further drive acceptance among both clinicians and individuals managing diabetes.
Based on the global empagliflozin (jardiance) regional forecast, European expansion is propelled by harmonized regulatory standards that streamline market entry, alongside strong national healthcare reimbursement schemes that prioritize innovative diabetes treatments. Clinical guidelines across the region increasingly recognize empagliflozin for its cardiovascular and renal protection, prompting clinicians to integrate it early in therapeutic regimens. Collaborative research networks generate robust real‑world data, reinforcing confidence among prescribers and payers. Additionally, focused physician engagement programs and patient education campaigns raise awareness of the drug’s benefits, while health technology assessment bodies often endorse its cost‑effectiveness, enabling swift formulary inclusion. These factors collectively accelerate uptake across key European markets.
Empagliflozin (jardiance) market in Germany enjoys prominent placement within national diabetes treatment guidelines, reflecting strong clinical endorsement. Health insurance funds provide comprehensive coverage, reducing barriers to patient access. Physician societies actively disseminate outcome data, reinforcing the drug’s role in managing cardiovascular risk. Integrated care models promote coordinated prescribing practices, ensuring consistent utilization across outpatient settings.
Empagliflozin (jardiance) market in United Kingdom is advancing rapidly due to endorsement by national clinical commissioning groups that prioritize innovative therapies. The drug is frequently included in diabetes pathways within primary care networks, facilitating early adoption. Educational initiatives aimed at general practitioners emphasize its dual benefits for glycemic control and organ protection. Patient assistance schemes further ease access, while ongoing post‑marketing studies sustain clinician confidence in its long‑term efficacy.
Empagliflozin (jardiance) market in France is emerging as a valued option within French diabetes management protocols, supported by favorable reimbursement decisions. Specialist endocrinology societies champion its inclusion based on clinical trial evidence, driving prescription momentum. Collaborative programs between hospitals and community pharmacies streamline dispensing processes. Public health campaigns raise awareness of the drug’s added cardiovascular benefits, encouraging both physicians and patients to consider it as a preferred therapeutic choice.
As per global empagliflozin (jardiance) regional outlook, Asia Pacific is enhancing its industry position through expanding healthcare coverage, rising diabetes prevalence, and growing physician familiarity with the drug’s comprehensive benefits. Regional regulatory agencies have facilitated efficient approval pathways, while national formularies increasingly incorporate empagliflozin as a preferred agent. Strategic partnerships between multinational manufacturers and local distributors improve supply chain robustness, ensuring consistent availability. Educational outreach targeting both specialists and primary care providers highlights real‑world outcomes, fostering confidence in prescribing. Additionally, patient‑centric programs address adherence challenges, further solidifying the drug’s adoption across diverse markets within the region.
Empagliflozin (jardiance) market in Japan is integrated into national diabetes treatment guidelines that emphasize cardiovascular risk mitigation. Health insurers provide generous coverage, encouraging widespread prescription. Collaborative clinical networks disseminate outcome data, reinforcing prescriber confidence. Patient support initiatives focus on education and monitoring, supporting long‑term adherence across the Japanese diabetic population.
Empagliflozin (jardiance) market in South Korea benefits from strong endorsement by the Korean Diabetes Association, which highlights its dual metabolic and organ‑protective effects. National insurance schemes facilitate reimbursement, reducing financial obstacles for patients. Ongoing physician education programs stress evidence‑based use, while hospital formularies prioritize its inclusion, driving consistent uptake throughout the healthcare system.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Diabetes Prevalence
Favorable Reimbursement Policies
High Treatment Cost
Regulatory and Safety Concerns
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape in the global empagliflozin (jardiance) market outlook is shaped by aggressive portfolio expansions, strategic mergers, and collaborative research agreements. Large pharmaceutical groups are securing exclusive licensing deals and co‑developing next‑generation SGLT2 inhibitors, while also acquiring niche biotech firms to broaden their cardiovascular‑renal pipelines. Partnerships with diagnostic companies are accelerating companion‑test development, and investments in digital adherence platforms are differentiating product offerings in a crowded market.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the primary driver is the rising prevalence of type 2 diabetes which fuels steady demand for empagliflozin’s proven cardiovascular benefits while a second driver is its expanding use in heart failure and chronic kidney disease that broadens the patient base. The global empagliflozin (jardiance) industry is led by North America where mature reimbursement systems and high insurer coverage sustain growth and the dominating segment remains the type 2 diabetes indication that accounts for the bulk of prescriptions. However, high treatment cost acts as a restraint limiting adoption in price‑sensitive regions and prompting payers to favour cheaper alternatives, the overall outlook remains robust with continued investment in digital therapeutics and real‑world evidence programmes.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 18.62 Billion |
| Market size value in 2033 | USD 49.2 Billion |
| Growth Rate | 11.4% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Empagliflozin (Jardiance) Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Empagliflozin (Jardiance) Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Empagliflozin (Jardiance) Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Empagliflozin (Jardiance) Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Empagliflozin (Jardiance) Market size was valued at USD 18.62 Billion in 2024 and is poised to grow from USD 20.74 Billion in 2025 to USD 49.2 Billion by 2033, growing at a CAGR of 11.4% during the forecast period (2026-2033).
The competitive landscape for empagliflozin is shaped by aggressive portfolio expansions, strategic mergers, and collaborative research agreements. Large pharmaceutical groups are securing exclusive licensing deals and co‑developing next‑generation SGLT2 inhibitors, while also acquiring niche biotech firms to broaden their cardiovascular‑renal pipelines. Partnerships with diagnostic companies are accelerating companion‑test development, and investments in digital adherence platforms are differentiating product offerings in a crowded market. 'Boehringer Ingelheim International GmbH', 'Eli Lilly and Company', 'Lupin Limited', 'Torrent Pharmaceuticals Ltd.', 'Dr. Reddy's Laboratories Limited', 'Sun Pharmaceutical Industries Limited', 'Zydus Lifesciences Limited', 'Cipla Limited', 'Aurobindo Pharma Limited', 'Alkem Laboratories Limited', 'Macleods Pharmaceuticals Limited', 'Glenmark Pharmaceuticals Limited', 'Intas Pharmaceuticals Ltd.', 'MSN Laboratories Pvt. Ltd.', 'Hetero Labs Limited', 'Biocon Limited', 'Sandoz Group AG', 'Teva Pharmaceutical Industries Ltd.', 'Viatris Inc.', 'STADA Arzneimittel AG'
The rising global incidence of type 2 diabetes creates sustained demand for effective glucose‑lowering therapies, positioning empagliflozin as a preferred option due to its proven cardiovascular benefits. Healthcare providers increasingly prioritize agents that address both glycemic control and comorbid risk, fostering broader prescription across primary and specialty care. Patient awareness of long‑term complications further drives adoption, as individuals seek treatments that offer improved outcomes. Such endorsement streamlines formulary inclusion worldwide.
Expanding Indications Beyond Diabetes: Pharmaceutical manufacturers are actively pursuing clinical trials that explore empagliflozin’s cardiovascular, renal and heart‑failure benefits, positioning the drug as a multi‑indication therapy. This broader therapeutic scope attracts specialty physicians, expands formulary placements, and encourages integrated treatment protocols across chronic disease management programs. As insurers recognize the value of a single agent addressing several comorbidities, prescribing patterns shift toward earlier adoption, reinforcing market momentum and creating new growth avenues beyond the traditional type‑2 diabetes patient base in key healthcare markets worldwide over.
Why does North America Dominate the Global Empagliflozin (Jardiance) Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
